John Kuelper

John Kuelper joined Ascension Ventures in 2014 as a Kauffman Fellow. Prior to Ascension Ventures, John was a student in Northwestern University’s accelerated MBA/JD program, graduating with distinction. He has worked with investment firms including Adams Street Partners, Sterling Partners and Abundant Venture Partners. John is Founder and CEO of Orpheden Therapeutics, a cancer immunotherapy business which is commercializing an autologous dendritic cell therapy platform, and Qualia Holdings, a healthcare services holding company which began as an enterprise data management and analytics business targeting the life sciences industry. John began his career as a medical researcher studying computational neuroscience and medical robotics and has over fifteen years of experience as a commercial software developer. In addition to MBA and JD degrees, he holds a BA in cognitive neuroscience from Washington University in St. Louis, graduating magna cum laude.